Nephrology/pediatric nephrology

August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS68
Academic Journal
Presents an abstract of the research manuscript `Transfusion and recombinant human erythropoietin (rhEPO) requirements differ between dialysis modalities,' by A.A. House et al.


Related Articles

  • How important is transfusion avoidance in 2013? Macdougall, Iain C.; Obrador, Gregorio T. // Nephrology Dialysis Transplantation;May2013, Vol. 28 Issue 5, p1092 

    Prior to the advent of recombinant erythropoietin in the late-1980s, blood transfusions were the mainstay of anaemia management in patients with end-stage renal failure, many of whom required “top-up” transfusions every 2 to 4 weeks to relieve the debilitating symptoms of severe...

  • Recombinant erythropoietin and blood transfusion in selected preterm infants. Meyer, M.P.; Sharma, E.; Carsons, M. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2003, Vol. 88 Issue 1, pF41 

    Objectives: To comprehensively identify preterm infants likely to require blood transfusion and to investigate the effectiveness of recombinant erythropoietin in this high risk subgroup. Design: Double blind randomised controlled trial. Setting: Neonatal Intensive Care Unit, Middlemore Hospital,...

  • Treatment of β-Thalassemia Patients with Recombinant Human Erythropoietin: Effect on Transfusion Requirements and Soluble Adhesion Molecules. Chaidos, Aristeidis; Makis, Alexandros; Hatzimichael, Eleftheria; Tsiara, Stavroula; Gouva, Maria; Tzouvara, Evangelia; Bourantas, Konstantinos L. // Acta Haematologica;2004, Vol. 111 Issue 4, p189 

    The most common single genetic disorder and a major public health issue in Greece and other Mediterranean countries is β-thalassemia. Current therapeutic approaches for homozygous β-thalassemia entail blood transfusions and iron chelation therapy with deferoxamine or deferiprone for...

  • DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Costa, Elísio; Rocha, Susana; Rocha-Pereira, Petronila; Reis, Flávio; Castro, Elisabeth; Teixeira, Frederico; Miranda, Vasco; Faria, Maria do Sameiro; Loureiro, Alfredo; Quintanilha, Alexandre; Belo, Luís; Santos-Silva, Alice // Acta Haematologica;Oct2008, Vol. 120 Issue 1, p11 

    The article presents a study which examined 63 chronic kidney disease (CKD) patients under haemodialysis and recombinant human erythropoietin (rhEPO) treatment, including 32 responders and 31 non-responders to rhEPO therapy. No statistically significant difference was noted in total iron...

  • Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. Costa, Elísio; Swinkels, Dorine W.; Laarakkers, Coby M.; Rocha-Pereira, Petronila; Rocha, Susana; Reis, Flávio; Teixeira, Frederico; Miranda, Vasco; Faria, Maria do Sameiro; Loureiro, Alfredo; Quintanilha, Alexandre; Belo, Luís; Santos-Silva, Alice // Acta Haematologica;Dec2009, Vol. 122 Issue 4, p226 

    The article discusses a study on the association of hepcidin serum levels and haematological data as well as iron status and recombinant human erythropoietin (rhEPO) doses in haemodialysis (HD) patients. The study had 33 HD patients undergoing rhEPO treatment on an average of 36 months using the...

  • Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient. Makis, A.C.; Chaliasos, N.; Hatzimichael, E. C.; Bourantas, K. L. // Annals of Hematology;Aug2001, Vol. 80 Issue 8, p492 

    We report on a 28-year-old patient with transfusion-dependent beta-thalassemia major, who was treated effectively with recombinant human erythropoietin (rHuEpo). rHuEpo promotes the differentiation and proliferation of erythroid cells, induces the production of fetal hemoglobin (HbF), and could...

  • Multicenter trial of one HLA-DR–matched or mismatched blood transfusion prior to cadaveric renal transplantation. Hiesse, Christian; Busson, Marc; Buisson, Claude; Farahmand, Hossein; Bierling, Philippe; Benbunan, Marc; Bedrossian, Janine; Aubert, Philippe; Glotz, Denis; Loirat, Chantal; Rondeau, Eric; Viron, Béatrice; Bleux, Helène; Lang, Philippe // Kidney International;Jul2001, Vol. 60 Issue 1, p341 

    Multicenter trial of one HLA-DR–matched or mismatched blood transfusion prior to cadaveric renal transplantation. Background. The beneficial effect of blood transfusions before cadaveric renal transplantation on allograft survival, although previously well documented, has become...

  • Sustained low efficiency dialysis using a singlepass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Schwenger, Vedat; Weigand, Markus A; Hoffmann, Oskar; Dikow, Ralf; Kihm, Lars P; Seckinger, J�rg; Miftanir, Mexhat; Schaier, Matthias; Hofer, Stefan; Haar, Caroline; Nawroth, Peter P; Zeier, Martin; Martin, Eike; Morath, Christian // Critical Care;2012, Vol. 16 Issue 4, p11445 

    Abstract: Introduction: Acute kidney injury (AKI) is associated with a high mortality of up to 60%. The mode of rena lreplacement therapy (intermittent versus continuous) has no impact on patient survival. Sustained low efficiency dialysis using a single-pass batch dialysis system (SLED-BD) has...

  • The Efficacy of Intravenous versus Subcutaneous Recombinant Erythropoietin in Obese African-African Patients in a Southeast U.S. Dialysis Cohort. Csongrádi, Éva; Shoemaker-Moyle, Michael; Zsom, Lajos; Wells, Catherine; Lengvárszky, Zsolt; Tapolyai, Mihály; Fülöp, Tibor // British Journal of Medicine & Medical Research;1/1/2014, Vol. 4 Issue 1, p184 

    Aims: To correct renal anemia, subcutaneous (SC) route of recombinant human erythropoietin (rhuEPO) administration has been associated with increased efficacy and decreased dose requirements, when compared with intravenous (IV) route. The effect of obesity as a potential modifier during rhuEPO...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics